Novartis AG ADR (NVS)vsOPTIMIZERx Corp (OPRX)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
OPRX
OPTIMIZERx Corp
$5.11
-5.02%
HEALTHCARE · Cap: $95.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 52607% more annual revenue ($56.58B vs $107.34M). NVS leads profitability with a 23.9% profit margin vs 6.4%. OPRX appears more attractively valued with a PEG of 1.61. OPRX earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
OPRX
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for OPRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 5.3% — below average capital efficiency
6.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OPRX
The strongest argument for OPRX centers on Price/Book, Debt/Equity, P/E Ratio.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : OPRX
The primary concerns for OPRX are PEG Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while OPRX is a value play — different risk/reward profiles.
OPRX carries more volatility with a beta of 1.10 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 49/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →OPTIMIZERx Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
OptimizeRx Corporation is a digital health company providing communications solutions for life sciences companies, physicians, and patients. The company is headquartered in Rochester, Michigan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?